Palo Alto Medical Foundation

Palo Alto Medical Research Foundation

Fausto G Araujo

Jack S Remington

A method of reducing the severity of toxoplasmosis resulting from infection of a patient with Toxoplasma gondii by administering to a patient in need of such treatment, either after infection or before exposure to infection, a therapeutically effective amount of a compound that is a spiropiperidyl derivative of rifamycin S, wherein the derivative comprises an imidazole ring that includes carbons at positions 3 and 4 of the rifamycin ring, the carbon at position 2 of the imidazole ring also being a ring carbon at position 4 of a piperidine ring system, thereby forming a spiropiperidyl ring system, the spiropiperidyl ring system optionally comprising a lower hydrocarbon substituent on the nitrogen of the piperidine.

Treatment for toxoplasmosis with a composition comprising a folate

Treatment for toxoplasmosis with a composition comprising a lincosamide

Treatment for toxoplasmosis with a composition comprising a sulfonamide

A method of reducing the severity of toxoplasmosis resulring from infection of a patient with Toxoplasma gondii by administering to a patient in need of such treatment, either after infection or before exposure to infection, a therapeutically effective amount of a compound that is a spiropiperidyl derivative of rifamycin S, wherein the derivative comprises an imidazole ring that includes carbons at positions 3 and 4 of the rifamycin ring, the carbon at position 2 of the imidazole ring also being a ring carbon at position 4 of a piperidine ring system, thereby forming a spiropiperidyl ring system, the spiropiperidyl ring system optionally comprising a lower hydrocarbon substituent on the nitrogen of the piperidine.

Treatment for toxoplasmosis with a composition comprising a macrolide

A method of reducing the severity of toxoplasmosis resulting from infection of a patient with Toxoplasma gondii by administering to a patient in need of such treatment, either after infection or before exposure to infection, a therapeutically effective amount of a compound that is a spiropiperidyl derivative of rifamycin S, wherein the derivative comprises an imidazole ring that includes carbons at positions 3 and 4 of the rifamycin ring, the carbon at position 2 of the imidazole ring also being a ring carbon at position 4 of a piperidine ting system, thereby forming a spiropiperidyl ring system, the spiropiperidyl ring system optionally comprising a lower hydrocarbon substituent on the nitrogen of the piperidine.

treatment for toxoplasmoisis with a composition containing a

Treatment for toxoplasmosis

An improved sandwich immunoassay for Toxoplasma gondii antigens associated with acute forms of Toxoplasma infection is disclosed. The assay employs either an F(ab').sub.2 fragment of IgG which reacts specifically with such antigens or a monoclonal antibody for such antigens as the substrate layer in the sandwich. The assay is sensitive and, unlike prior sandwich assays for the antigen, is not affected significantly by cross-reactions with rheumatoid factor.

Growing community of inventors

Palo Alto, CA, United States of America

Fausto G Araujo